Practice parameter
Drug Allergy: An Updated Practice Parameter

https://doi.org/10.1016/j.anai.2010.08.002Get rights and content

Section snippets

Chief Editors

Roland Solensky, MD, and David A. Khan, MD

Workgroup Contributors

I. Leonard Bernstein, MD; Gordon R. Bloomberg, MD; Mariana C. Castells, MD, PhD; Louis M. Mendelson, MD; and Michael E. Weiss, MD

Task Force Reviewers

David I. Bernstein, MD; Joann Blessing-Moore, MD; Linda Cox, MD; David M. Lang, MD; Richard A. Nicklas, MD; John Oppenheimer, MD; Jay M. Portnoy, MD; Christopher Randolph, MD; Diane E. Schuller, MD; Sheldon L. Spector, MD; Stephen Tilles, MD; and Dana Wallace, MD

Reviewers

Paul J. Dowling, MD – Kansas City, MO

Mark Dykewicz, MD – Winston-Salem, NC

Paul A. Greenberger, MD – Chicago, IL

Eric M. Macy, MD – San Diego, CA

Kathleen R. May MD – Cumberland, MD

Myngoc T. Nguyen, MD – Piedmont, CA

Lawrence B. Schwartz, MD, PhD – Richmond, VA

Contributors

The Joint Task Force has made a concerted effort to acknowledge all contributors to this parameter. If any contributors have been excluded inadvertently, the Task Force will ensure that appropriate recognition of such contributions is made subsequently.

Chief Editors

  • Roland Solensky, MD

  • Division of Allergy and Immunology

  • The Corvallis Clinic

  • Corvallis, Oregon

  • David A. Khan, MD

  • Professor of Medicine

  • Division of Allergy & Immunology

  • University of Texas Southwestern Medical Center

  • Dallas, Texas

Workgroup Contributors

  • I. Leonard Bernstein, MD

  • Professor of Clinical Medicine

  • University of Cincinnati College of Medicine

  • Cincinnati, Ohio

  • Gordon R. Bloomberg, MD

  • Associate Professor, Department of Pediatrics

  • Division of Allergy & Pulmonary Medicine

  • Washington University School of Medicine

  • Saint Louis, Missouri

  • Mariana C. Castells, MD, PhD

  • Director, Desensitization Program

  • Associate Director, Allergy Immunology Training Program

  • Brigham & Women's Hospital

  • Harvard Medical School

  • Boston, Massachusetts

  • Louis M. Mendelson, MD

  • Clinical

Task Force Reviewers

  • David I. Bernstein, MD

  • Department of Clinical Medicine, Division of Immunology

  • University of Cincinnati College of Medicine

  • Cincinnati, Ohio

  • Joann Blessing-Moore, MD

  • Department of Immunology

  • Stanford University Medical Center

  • Palo Alto, California

  • Linda Cox, MD

  • Department of Medicine

  • Nova Southeastern University

  • Davie, Florida

  • David M. Lang, MD

  • Allergy/Immunology Section, Division of Medicine

  • Cleveland Clinic Foundation

  • Cleveland, Ohio

  • Richard A. Nicklas, MD

  • Department of Medicine

  • George Washington Medical Center

Preface

The objective of “Drug Allergy: An Updated Practice Parameter” is to improve the care of patients by providing the practicing physician with an evidence-based approach to the diagnosis and management of adverse drug reactions. This document was developed by a Working Group under the aegis of the Joint Task Force on Practice Parameters, which has published 26 practice parameters and updated parameters for the field of allergy/immunology (these can be found online at www.jcaai.org). The 3

Classification of Adverse Reactions to Drugs

Adverse drug reactions (ADRs) result in major health problems in the United States in both the inpatient and outpatient settings. ADRs are broadly categorized into predictable (type A) and unpredictable (type B) reactions. Predictable reactions are usually dose dependent, are related to the known pharmacologic actions of the drug, and occur in otherwise healthy individuals. They are estimated to comprise approximately 80% of all ADRs. Unpredictable reactions are generally dose independent, are

First page preview

First page preview
Click to open first page preview

References (194)

  • D.M. Essayan et al.

    Successful parental desensitization to paclitaxel

    J Allergy Clin Immunol

    (1996)
  • M.C. Castells et al.

    Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases

    J Allergy Clin Immunol

    (2008)
  • A. Goldberg et al.

    A modified, prolonged desensitization protocol in carboplatin allergy

    J Allergy Clin Immunol

    (1996)
  • C. Garufi et al.

    Skin testing and hypersensitivity reactions to oxaliplatin

    Ann Oncol

    (2003)
  • N. Absar et al.

    Desensitization to trimethoprim/sulfamethoxazole in HIV-infected patients

    J Allergy Clin Immunol

    (1994)
  • J. Belchi-Hernandez et al.

    Management of adverse reactions to prophylactic trimethoprim-sulfamethoxazole in patients with human immunodeficiency virus infection

    Ann Allergy Asthma Immunol

    (1996)
  • V. Kalanadhabhatta et al.

    Successful oral desensitization to trimethoprim-sulfamethoxazole in acquired immune deficiency syndrome

    Ann Allergy Asthma Immunol

    (1996)
  • J.D. Rich et al.

    Trimethoprim/sulfamethoxazole incremental dose regimen in human immunodeficiency virus-infected persons

    Ann Allergy Asthma Immunol

    (1997)
  • P. Demoly et al.

    Six-hour trimethoprim-sulfamethoxazole-graded challenge in HIV-infected patients

    J Allergy Clin Immunol

    (1998)
  • P. Bonfanti et al.

    The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: a randomized multicentric study

    Biomed Pharmacother

    (2000)
  • S. Yoshizawa et al.

    A 5-day course of oral desensitization to trimethoprim/sulfamethoxazole (T/S) in patients with human immunodeficiency virus type-1 infection who were previously intolerant to T/S

    Ann Allergy Asthma Immunol

    (2000)
  • A. Carr et al.

    Allergy and desensitization to zidovudine in patients with acquired immunodeficiency syndrome (AIDS)

    J Allergy Clin Immunol

    (1993)
  • S. Duque et al.

    Zidovudine-related erythroderma and successful desensitization: a case report

    J Allergy Clin Immunol

    (1996)
  • Z. Temesgen et al.

    HIV and drug allergy

    Immunol Allergy Clin North Am

    (2004)
  • P.G. Clay

    The abacavir hypersensitivity reaction: a review

    Clin Ther

    (2002)
  • D. King et al.

    Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects

    J Allergy Clin Immunol

    (2005)
  • S. Hetherington et al.

    Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

    Lancet

    (2002)
  • W.J. Pichler

    Delayed drug hypersensitivity reactions

    Ann Intern Med

    (2003)
  • D.A. Schmid et al.

    Transfection of drug-specific T-cell receptors into hybridoma cells: tools to monitor drug interaction with T-cell receptors and evaluate cross-reactivity to related compounds

    Mol Pharmacol

    (2006)
  • M. Blanca et al.

    Clinical evaluation of Pharmacia CAP System RAST FEIA amoxicilloyl and benzylpenicilloyl in patients with penicillin allergy

    Allergy

    (2001)
  • C. Fontaine et al.

    Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate beta-lactam allergy

    Allergy

    (2007)
  • M.L. Sanz et al.

    Flow cytometric basophil activation test: a review

    J Investig Allergol Clin Immunol

    (2002)
  • P. Gamboa et al.

    The flow-cytometric determination of basophil activation induced by aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is useful for in vitro diagnosis of the NSAID hypersensitivity syndrome

    Clin Exp Allergy

    (2004)
  • M.L. Sanz et al.

    Flow cytometric basophil activation test by detection of CD63 expression in patients with immediate-type reactions to betalactam antibiotics

    Clin Exp Allergy

    (2002)
  • M.J. Torres et al.

    The diagnostic interpretation of basophil activation test in immediate allergic reactions to betalactams

    Clin Exp Allergy

    (2004)
  • A. Romano et al.

    Diagnosing nonimmediate reactions to penicillins by in vivo tests

    Int Arch Allergy Immunol

    (2002)
  • A. Barbaud et al.

    The use of skin testing in the investigation of cutaneous adverse drug reactions

    Br J Dermatol

    (1998)
  • M. Britschgi et al.

    T-cell involvement in drug-induced acute generalized exanthematous pustulosis

    J Clin Invest

    (2001)
  • E. Cuerda Galindo et al.

    Fixed drug eruption from piroxicam

    J Eur Acad Dermatol Venereol

    (2004)
  • P. Wolkenstein et al.

    Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis

    Contact Dermatitis

    (1996)
  • M. Bronnimann et al.

    Histopathology of drug-induced exanthems: is there a role in diagnosis of drug allergy?

    Curr Opin Allergy Clin Immunol

    (2005)
  • D.D. Sogn et al.

    Results of the National Institute of Allergy and Infectious Diseases collaborative clinical trial to test the predictive value of skin testing with major and minor penicillin derivatives in hospitalized adults

    Ann Intern Med

    (1992)
  • J. Gadde et al.

    Clinical experience with penicillin skin testing in a large inner-city STD clinic

    JAMA

    (1993)
  • C.E. Lee et al.

    The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance

    Ann Intern Med

    (2000)
  • A. Romano et al.

    Cross-reactivity and tolerability of cephalosporins in patients with immediate hypersensitivity to penicillins

    Ann Intern Med

    (2004)
  • A. Romano et al.

    Tolerability of meropenem in patients with IgE-mediated hypersensitivity to penicillins

    Ann Intern Med

    (2007)
  • A. Romano et al.

    Imipenem in patients with immediate hypersensitivity to penicillins

    N Engl J Med

    (2006)
  • B.L. Strom et al.

    Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics

    N Engl J Med

    (2003)
  • H. Heine

    Cutaneous adverse reaction to ciprofloxacin: demonstration of specific lymphocyte proliferation and cross-reactivity to ofloxacin in vitro

    Acta Dermato-Venereol

    (1997)
  • B. Sachs et al.

    Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use

    Drug Saf

    (2006)
  • Cited by (0)

    These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology; the American College of Allergy, Asthma and Immunology; and the Joint Council of Allergy, Asthma and Immunology.

    The American Academy of Allergy, Asthma and Immunology (AAAAI) and the American College of Allergy, Asthma and Immunology (ACAAI) have jointly accepted responsibility for establishing “Drug Allergy: An Updated Practice Parameter.” This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma and Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.

    Reprint requests: Joint Council of Allergy, Asthma & Immunology, 50 N. Brockway St, #3-3, Palatine, IL 60067.

    View full text